All News

Event-free survival, overall survival, and pathologic complete rate data from the phase 3 KEYNOTE-905 trial support the agency’s decision.

Sac-TMT demonstrated a significant improvement in PFS vs chemotherapy as first-line treatment for unresectable locally recurrent or metastatic TNBC.

The approval, based on the phase 3 TROPION-Breast02 trial, marks a significant shift in the first-line treatment of patients with mTNBC.

See which trials in lung, gastrointestinal, and genitourinary cancers to be on the lookout for at 2026 ASCO.

A telephone-based weight loss intervention from the phase 3 BWEL trial improved physical function, fatigue, and social role outcomes vs health education alone in patients with stage II to III breast cancer and BMI of at least 27.

The ArteraAI Prostate Test is now available to predict mortality risk and guide treatment for metastatic hormone-sensitive prostate cancer.

Jesus D. Anampa, MD, MS, discussed SEER database trends in chemotherapy use for older women with TBNC and explained the rationale for using breast cancer-free survival vs OS.

The FDA has granted rare pediatric disease designation and orphan drug designation to FL118 for the treatment of osteosarcoma.

Philip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.

Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium 224 Alpha DaRT in pancreatic adenocarcinoma.

The extended-release tablet formulation may help improve patient adherence to treatment, possibly representing a more convenient, patient-friendly dosing schedule, according to Naveen Pemmaraju, MD.

The agency set a Prescription Drug User Fee Act target action date for January 6, 2027, for patients with NMIBC with papillary tumors without CIS.

Investigators are assessing CLN-049 among patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome in a phase 1 study.

At ONS 2026, an oncology nurse specialist discussed the timing and pharmacy coordination required to administer a time-sensitive mitomycin gel.

This episode of The AI Oncology Revolution highlighted the nursing and APP teams and how they are leading the charge in AI implementation.

The INCIPIENT trial establishes CARv3-TEAM-E as a mechanistically sophisticated and biologically active platform for recurrent glioblastoma.

The investigational BCG-containing regimen conferred a weighted anytime CR rate of 69.7% vs 53.4% with nadofaragene firadenovec in this NMIBC group.

Statistical significance was not met with either dose level of fianlimab plus cemiplimab compared with the control arm for patients with advanced melanoma.

Investigators evaluated how subcutaneous isatuximab affected workflow and safety for patients with multiple myeloma.

Disease control was observed in all patients who received JNJ-1900 in part 1 of the phase 2 CONVERGE trial.

Sac-TMT was shown to be the first TROP2 ADC to improve survival vs chemotherapy in patients with endometrial cancer who progressed on chemo- and immunotherapy.

Investigators evaluated how tisagenlecleucel and cilta-cel altered adverse effect timelines for patients treated for hematologic malignancies.